Cipla will release its financial statement for the quarter ended September 30 and revenue growth is expected to come in at around 4 percent. Margins could stand at around 19 percent and a profit growth of around 12 percent on a year-on-year (YoY) basis.
In terms of the key factors, US growth is probably expected to come off as compared to the previous two quarters. Last quarter, US was up around 60 percent on a YoY basis. It was supported by a key drug called Sensipar generic where the contribution is expected to be slow as compared to the previous quarters.
Indian business is expected to bounce back. It was down around 12 percent last quarter. They had some distribution issues last quarter.
Emerging markets also was weak for the company in the last quarter, down around 40 percent. So any sort of recovery will be watched out for. Margin should be steady this time.
The commentary will be important for Cipla and that would be on the Goa facility which had recently been inspected by the US FDA as well as their pipeline of products for the US as well as guidance in terms of sales will be watched out for.